Interview: BioNTech And Pfizer Explore mRNA Flu Vaccines In $120m+ Deal

The German biotech's CBO and CCO Sean Marett tells Scrip that the Pfizer pact represents the first time BioNTech has moved into infectious disease in humans and could lead to higher potency flu vaccines that could be made more rapidly and cheaply.

Cash injection
BioNTech gets Pfizer cash injection for flu vaccine • Source: Shutterstock

Expanding from its personalized cancer immunotherapy area of expertise, Europe’s largest private biotech BioNTech AG has signed a collaboration with Pfizer Inc. to develop messenger RNA (mRNA)-based vaccines for the prevention of influenza.

The cash terms that the German group has negotiated are impressive. BioNTech will receive $120m in upfront, equity and near-term...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By 

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

Moderna Posts Phase III Efficacy Data For Flu Vaccine

 
• By 

With positive relative efficacy data for its mRNA seasonal flu shot, Moderna hopes to file mRNA-1010 for US approval and refile a COVID-19/flu combo shot that it withdrew in May.

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By 

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Industry’s Vaccines Pipeline In A Changing Regulatory Landscape

 

More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.

More from Therapy Areas

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.